SOURCE: Hydromedix Group, Inc.

April 11, 2007 09:15 ET

Dr. Kishore Dass Comments on Funding for Prototype Design

WEST PALM BEACH, FL -- (MARKET WIRE) -- April 11, 2007 -- Dr. Kishore Dass of the Regional Cancer Center in Wellington Florida is excited to see Hydromedix Group, Inc. (PINKSHEETS: HMXG) acquire financing to complete prototype design of patented technology. Dr. Dass comments, "It is nice to see Hydromedix is raising the funds to complete all of the phases of prototypes relating to the radiation oncology appendage pieces. I look forward to helping Hydromedix throughout this process and I am excited to see the benefits of the appendage pieces when they are ready for testing on our radiation patients." Hydromedix is extremely pleased to have the expertise of Dr. Dass assisting in the prototype design process and are extremely confident the appendage pieces pertaining to radiation therapy will address all customer concerns and improve the healing process more efficiently than traditional healing methods. Radiation therapy causes burns, and pain management is an issue oncology patients deal with during the radiation therapy process. Once the appendage pieces are completely designed and fully tested, they can be utilized prior to, during, and subsequent to the radiation therapy.

Dr. Kishore Dass, M.D., Medical Director of the Regional Cancer Center at Wellington Regional Medical Center

Under the direction of Dr. Kishore Dass, the Regional Cancer Center has quickly become a highly respected oncology center. Dr. Dass is a graduate of Loyola University Stritch School of Medicine and is an alumnus of the Cleveland Clinic Foundation in Cleveland, Ohio, where he was instrumental in the development of Stereotactic Radiosurgery. The philosophy of the staff at the center is to provide services in an environment that supports and promotes the highest quality of life, sensitive to the specific physical, psychological and educational needs of each patient. The Regional Cancer Center not only provides advanced diagnostics and cancer treatments, but also provides other important services to cancer patients, families and the community, such as prostate cancer and breast cancer support groups, nutritional counseling services, social services, nursing support, courtesy van transportation, free screenings and educational lectures.

About Hydromedix Group, Inc.

Hydromedix (www.hydromedix.com) operates within the 200+ Billion Dollar Medical Devices and Supply Industry and develops medical devices that accelerate the rate of healing of certain types of injuries. Upon completion of development of the products and appropriate testing, HMXG intends to market their products to a diverse market clientele, including medical offices, hospitals, long-term care facilities and physical therapists. Their Patented "Dry Contact Whirlpool Therapy" technology speeds the healing process for post-operative surgical patients, radiation therapy, and the rehabilitating process for injured athletes by applying heat or cold to the injured area in a more efficient and effective manner, thus having the potential to speed up the healing process a considerable amount compared to the traditional healing methods.

Safe Harbor

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," or "intent to" and similar conditional expressions are intended to identity forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional financings and other risks in the company's SEC reports and filings.

Contact Information